Biohaven enters mid-May with a familiar problem: a lot of people are betting against it, and that number keeps growing.
Short interest has climbed to just over 20% of the free float — roughly 25 million shares — and the pace of accumulation has picked up noticeably this week. SI jumped more than 5% over the past seven days alone, adding to a 14% build over the past month. Compare that to early April, when the short interest percentage sat closer to 18%. The move is steady and directional, not a single-session jump, which makes it harder to dismiss as noise.
The lending market adds a wrinkle that cuts against the bearish narrative, however. Borrow costs are cheap — running below 0.5% annualised — and availability is extremely loose. Only around 3% of available shares have actually been lent out, a fraction of the 52-week peak near 13%. That combination is unusual: heavy short interest in the float paired with a borrow market that barely registers demand. The most straightforward read is that the shorts already placed their bets months ago through other structures, or that availability is genuinely ample and borrowing friction is not a factor here either way. There is no squeeze pressure visible in the lending data. Options positioning is also not particularly defensive: the put/call ratio of 0.29 is above its 20-day average of 0.24 but well short of alarming, sitting less than one standard deviation from the mean and far below the 52-week high of 0.65.
The Street is broadly constructive but selectively trimming targets. Morgan Stanley's Terence Flynn kept his Overweight rating this morning while cutting his target from $21 to $18 — the second time this analyst has lowered his target this year. RBC Capital moved in the same direction last week, shaving its Outperform target from $23 to $22. Both firms remain positive on the name, but the direction of travel is lower. The consensus mean target is $21.76 against a current price of $9.20, implying the Street still sees more than 130% upside — a gap that reflects the binary nature of a clinical-stage biotech rather than a typical valuation call. On the bull side, the pipeline breadth and a management team with prior commercialisation track record support the thesis. Bears point to Biohaven's fast-follower positioning across multiple therapeutic areas — a strategy that spreads R&D spend thin — and specifically to opakalim's weaker competitive profile versus azetukalner in the focal onset seizure readout. The ORTEX short score of 63 and an analyst recommendation divergence ranking in the 92nd percentile suggest the two-sided debate is unusually wide.
Institutional ownership is concentrated. Janus Henderson reported a near-tripling of its position earlier this year to around 11% of shares, and Suvretta Capital and Stifel Asset Management each hold above 6%. Several holders — including Infinitum Asset Management and TCG Crossover — appear to have initiated new or substantially expanded positions as recently as year-end 2025. That concentration can cut both ways: it supports the stock if those managers add on weakness, but creates overhang risk if any one name decides to exit.
Earnings history offers a sobering pattern. The three most recent prints each produced a negative one-day move, ranging from a mild 0.8% gain on May 4 (which then reversed to a 5.7% loss over five days) to a 7.4% drop after the March 2 announcement. Five-day reactions have consistently been worse than the initial day, suggesting any relief rally after a print has tended not to hold. The next scheduled earnings event is August 6. Between now and then, the Phase 2/3 opakalim readout in focal onset seizures will be the data point that drives positioning in either direction more than any financial release.
See the live data behind this article on ORTEX.
Open BHVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
